Leukemia drug fights ovarian cancer

A drug commonly used to treat a certain form of leukemia has shown promising results in fighting ovarian cancer, the deadliest malignancy in the female population.

According to the study published in the British Medical Journal, dasatinib (Sprycel), the drug used to treat chronic myeloid leukemia, limits the growth and invasive powers of ovarian cancer cells.

Combining dasatinib with chemotherapy enforces its ability in fighting Src dependent cancer, which accounts for one-third of the ovarian cancer case.

"It is important to remember that this work is only on cancer cell lines, but it is significant enough that it should be used to justify clinical trials to confirm that women with this type of ovarian cancer could benefit," said lead researcher Gottfried Konecny.

Scientists are optimistic that their findings will lead to the development of new medication to fight ovarian cancer in the near future.

Source: PressTV.
Link: http://www.presstv.ir/detail.aspx?id=111254§ionid=3510210.